ResultsIQ

ResultsIQ › Latest results › Viyash Scientific Limited

Viyash Scientific Limited Q2 FY26 results deck summary

NSE: VIYASH · BSE: 512529

Results deck of 17 Nov 2025, summarised by AI from the filing.

NCLT approval order reserved on Oct 31, 2025; pronouncement expected soon; synergy focus for next 12 months.

Key takeaways

  1. Merger timeline NCLT approval order reserved on Oct 31, 2025; pronouncement expected soon; synergy focus for next 12 months.
  2. Growth drivers New product launches, focus on CDMO business, improved product mix, network optimisation, backward and forward integration.
  3. Merger risk Merger completion depends on NCLT approval order pronouncement, which is still awaited.

Original filing on BSE

Viyash Scientific Limited Q1 FY27 results

As filed: Revenue ₹946 cr, EBITDA ₹178 cr, PAT ₹79.3 cr, EBITDA margin 18.9%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹946 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹920 cr, EBITDA ₹184 cr, PAT ₹66.4 cr, EBITDA margin 20.0%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹920 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +11.0% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹858 cr, EBITDA ₹176 cr, PAT ₹48.5 cr, EBITDA margin 20.5%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹858 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +11.7% in 30 days (Nifty 500: +2.5%).

Past price moves after results do not indicate future moves. Not a recommendation.

Viyash Scientific Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.